News & Updates
Filter by Specialty:
Biweekly cabazitaxel plus G-CSF beneficial to certain older mCRPC patients
In the treatment of older patients with metastatic castration-resistant prostate cancer (mCRPC) who are considered unsuitable candidates for standard cabazitaxel (CBZ) regimens, treatment with CBZ at 16 mg/m2 (biweekly CBZ16) plus prophylactic granulocyte colony–stimulating factor (G-CSF) at each cycle helps reduce the risk of higher grade neutropenia and/or neutropenic complications while yielding similar clinical outcomes, according to the results of the phase III CABASTY trial.
Biweekly cabazitaxel plus G-CSF beneficial to certain older mCRPC patients
27 Nov 2023
177Lu-PSMA-617 improves rPFS vs ARPI switch in taxane-naïve mCRPC patients
The prostate-specific membrane antigen (PSMA)–targeted radioligand, lutetium-177 (177Lu)–PSMA-617, improves radiographic progression-free survival (rPFS) vs androgen receptor pathway inhibitor (ARPI) switch and has a favourable safety profile in taxane-naïve patients with metastatic castration-resistant prostate cancer (mCRPC) progressing on one prior second-generation ARPI, results of the phase III PSMAfore trial have shown.
177Lu-PSMA-617 improves rPFS vs ARPI switch in taxane-naïve mCRPC patients
14 Nov 2023
Multimodal intervention reduces second-line antibiotic prescriptions for UTI
A multimodal intervention applied in general practice results in a significant decrease in antibiotic prescribing and an increase in guideline adherence among women with uncomplicated urinary tract infection (UTI), a study has shown.
Multimodal intervention reduces second-line antibiotic prescriptions for UTI
13 Nov 2023
Serum vitamin A, E forms tied to prostate cancer risk
Several forms of serum vitamin A and E were associated with prostate cancer risk, with significant effect modification by smoking and alcohol consumption status, according to an analysis that used data from the Singapore Prostate Cancer Study.
Serum vitamin A, E forms tied to prostate cancer risk
08 Nov 2023
Enfortumab vedotin-pembrolizumab beats chemo as 1L Tx for bladder cancer
In the phase III EV-302/KEYNOTE-A39 trial, the combination of enfortumab vedotin and pembrolizumab (EV+P) had a significant survival advantage over chemotherapy in the first-line treatment of patients with locally advanced metastatic urothelial carcinoma (la/mUC).
